ECTRIMS 2021 | Markers of axonal damage in progressive MS
To accelerate the development of novel therapies targeting progression in multiple sclerosis (MS), quantifiable and objective biomarkers that reflect the non-inflammatory component of MS pathology are needed. In recent years, several fluid biomarkers have demonstrated clinical relevance in the relapsing-remitting space, useful for MS diagnosis and prognosis as well as for the assessment of therapy response. Charlotte Teunissen, PhD, VU University Medical Center Amsterdam, The Netherlands, discusses the importance of developing biomarkers that reflect axonal damage, a process responsible for irreversible progression in MS, which can be used to monitor the effectiveness of therapies for progressive disease. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress 2021.
Disclosures
Research of Prof. Teunissen is supported by the European Commission (Marie Curie International Training Network, grant agreement No 860197 (MIRIADE), and JPND), Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands, Alzheimer Association.
Prof. Teunissen is a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds.
Prof. Teunissen has a collaboration contract with ADx Neurosciences, Quanterix, and Eli Lilly, performed contract research or received grants from AC-Immune, Axon Neurosciences, Biogen, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, PeopleBio, Roche, Toyama, and Vivoryon.
